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We read with great interest the elegant review entitled
‘Hereditary angioedema: the plasma contact system out
of control’ by De Maat et al. recently published in the
Journal of Thrombosis and Haemostasis. [1]. In particular,
we appreciated the section on the possible role of
angiopoietins (Angs) and vascular endothelial growth fac-
tors (VEGFs) in the modulation of vascular permeability
in patients with hereditary angioedema. The authors cor-
rectly mentioned our recent article in which we identified
a substitution mutation in ANGPT1 associated with
hereditary angioedema [2]. In addition, at the end of the
same paragraph, De Maat et al. discussed the possibility
that the vasoactive mediator VEGF could contribute to
the destabilization of vascular permeability in patients
with hereditary angioedema. This hypothesis was also
illustrated in Fig. 3 of the review, showing VEGF activat-
ing VEGF receptor (VEGFR) on endothelial cells [1]. In
the same figure, it is shown that Ang1 activates the TIE2
receptor expressed on endothelial cells.
We would like to highlight the complexity of the
interactions between different VEGFs and Angs and
their receptors expressed on endothelial cells and also
on certain immune cells. VEGF-A was initially
discovered and named vascular permeability factor
(VPF) [3]. In fact, the group of Dvorak demonstrated
that ascites fluids from a variety of tumors and super-
natants from several tumor cell lines contained an
activity (i.e. VPF) that rapidly increased microvascular
permeability. The vasodilating activity of VPF/VEGF-A
is at least 50-fold more potent than that of histamine
[3].
There is now compelling evidence that the VEGF family
includes several isoforms such as VEGF-B, VEGF-C,
VEGF-D, and placental growth factor, in addition to
VEGF-A [4]. Moreover, there are several splicing isoforms
of VEGF-A (121, 165, 189, and 206) that differ in their
binding to matrix and specific receptors and coreceptors.
For example, VEGF-A121 is acidic and freely diffusible,
whereas VEGF-A165, VEGF-A189 and VEGF-A206 are
basic, and also bind to heparin and heparin proteoglycans
on cellular surfaces and extracellular matrices [4]. VEGFs
bind with different specificities to three mainly endothelial
transmembrane receptors, i.e. VEGFR-1, VEGFR-2, and
VEGFR-3 [5]. The angiogenic and permeability activities
of VEGF-A are mediated by interaction with VEGFR-2,
whereas the lymphangiogenic activity is promoted by bind-
ing to a VEGFR-2–VEGFR-3 heterodimer receptor.
Additional molecules, such as Ang1 and Ang2, modu-
late endothelial junctions through the engagement of two
cell surface tyrosine kinase receptors, i.e. TIE1 and TIE2
[6]. Ang1 is expressed by perivascular cells, such as peri-
cytes, and sustains endothelial cell survival. In contrast,
Ang2, which is secreted by endothelial cells, acts autocrin-
ally and paracrinally as a TIE2 ligand to promote angio-
genesis and vascular permeability. TIE2 is primarily
expressed on endothelial cells and binds both Angs,
whereas TIE1 is an orphan receptor that can modulate
TIE2 activity.
During recent years, it has become evident that sev-
eral circulating (e.g. basophils, neutrophils, monocytes,
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and eosinophils) and tissue-resident (e.g. macrophages
and mast cells) immune cells are important sources of
different isoforms of VEGFs and Angs during inflam-
mation [7–9]. More recently, we have provided the first
evidence that activated human peripheral blood neu-
trophils can also release VEGF-A165b, which antagonizes
the effects of VEGF-A [9]. Collectively, the above find-
ings highlight the complexity of the VEGF–VEGFR
and Ang–TIE interactions between circulating immune
and endothelial cells, which may also be important in
angioedema.
We would like to respectfully note that our group,
for the first time, demonstrated that the levels of two
different forms of VEGF (VEGF-A and VEGF-C) and
Angs (Ang1 and Ang2) are increased in the plasma of
asymptomatic patients with hereditary angioedema as
compared with healthy controls [10]. Moreover, the
levels of VEGF-A, VEGF-C and Ang2 are also
increased in patients experiencing a higher number of
angioedema attacks each year. The relevance of these
findings is supported by the correlation of plasma levels
of VEGF-A and Ang2 with those of cleaved high
molecular weight kininogen, which is a precursor of
bradykinin. In the same article, we hypothesized that
VEGFs and Angs, along with increased release of bra-
dykinin, can induce a state of vascular preconditioning
that may change the threshold for the development of
angiodema attacks [10].
We would like to emphasize the above findings,
because the results of our study, which represented the
first evidence that VEGFs and Angs are possibly involved
in hereditary angioedema, were not discussed in the
review by De Maat et al.
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